{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Screening', 'Extension', 'Every 3', 'End of', 'Survival', 'Period for', 'Cycle 1/Day', 'weeks, +3', 'Extension', 'Follow-Up4', 'Extension', '1 (EC1D1)', 'days', 'Phase (up to', 'Phase (28 days)', '(EC1D22', '96 weeks)', '1,2', 'through', '30 days', 'EC16D22)', '7 days after', 'last dose of', 'cemiplimab', 'CT=computed tomography; ECOG PS=Eastern Cooperative Oncology Group Performance Status;', 'IV=intravenous; MRI=magnetic resonance imaging; TSH=thyroid stimulating hormone;', 'WOCBP=women of childbearing potential', '7.1.7.2.', 'Footnotes for the Schedule of Events Table 3 for the Cemiplimab Extension', 'Phase', '1. Written informed re-consent for the cemiplimab Extension Phase must be provided prior', 'to the initiation of screening procedures and must be obtained within 45 days prior to first', 'dose of cemiplimab in the Extension Phase of the study. All screening assessments must', 'be performed within 28 days prior to first dose of cemiplimab in the Extension Phase.', 'Assessments performed as part of standard of care that fall within the screening window,', 'but before informed consent is obtained, may be used for screening and do not need to be', 'repeated for eligibility.', '2.', 'Patients who are currently receiving cemiplimab will transition to the cemiplimab', 'Extension Phase. Their Extension Phase treatment day should correspond to their current', 'treatment day, such that they may receive up to 96 weeks of total cemiplimab therapy', '(inclusive of cemiplimab received prior to the cemiplimab Extension Phase). These', 'patients do not need to repeat screening procedures.', '3. Total duration of cemiplimab therapy is up to 96 weeks, or PD, or unacceptable toxicity.', '4. After the end of treatment, survival follow-up assessments will occur every 90 days', '(+10 days) until death or study termination per sponsor. Telephone assessments are', 'acceptable. Regeneron may request that survival data be collected on all randomized', 'participants outside of the 90-day specified window. At the time of this request, each', 'participant will be contacted to determine their survival status unless the patient has', 'withdrawn consent for all contact.', '7.2.', 'Study Procedures', '7.2.1.', 'Procedures Performed at the Screening Visit', 'The following procedures will be performed for the sole purpose of determining study eligibility', 'or characterizing the baseline population:', 'Serum \u00df-HCG (result must be 72 hours before first dose)', 'HBV, HCV, and HIV screening: hepatitis B surface antigen, hepatitis C positive RNA', '(positive hepatitis C antibody test will require hepatitis C RNA test to rule out active', 'infection), HIV-1, or HIV-2 serum antibody', 'Regeneron Pharmaceuticals, Inc.', 'Page 60 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Documentation of pathologic confirmation of cervical cancer (SCC', 'or', 'adenocarcinoma/AC prior to Amendment 5; squamous cell histology only starting with', 'Amendment 5)', 'Pathology material (formalin-fixed paraffin-embedded [FFPE] block or 20 slides from', 'the sample in the submitted pathology report). This material will be used for correlative', 'science studies (Section 7.2.7).', 'Patients who fail screening may be screened one additional time and an ICF will need', 'to be signed at the re-screen. Some procedures may not need to be repeated if they', 'were previously completed within 28 days prior to cycle 1 day 1.', '7.2.2.', 'Efficacy Procedures', 'For all patients, disease will be measured radiologically according to RECIST 1.1 criteria', '(Appendix 1; Eisenhauer 2009). The CT or MRI for tumor assessment will be performed in', 'screening, during treatment, and during follow-up, as detailed in Table 1 and Table 2. During the', 'treatment period, tumor response assessments are performed at end of cycles 1 through 4, 6, 8, 10,', '12, 14, and 16 (Table 1). During follow-up, tumor response assessments are performed at follow-', 'up visits 1 and 2 (Table 2). The choice of whether the imaging is by CT or MRI is an investigator', 'decision. Once the choice of CT scan or MRI has been made, subsequent assessments should be', 'made using the same modality whenever possible.', 'Whole-body (chest/abdomen/pelvis) imaging is performed at the baseline assessment', 'and is strongly recommended at each response assessment. A CT or MRI of the neck', 'should be performed in patients with metastases to neck. At a minimum, all', 'radiologically measurable target lesions (RECIST 1.1) should be imaged at each', 'response assessment. The same radiologic imaging modality should be used at each', 'response assessment.', 'Brain imaging - MRI brain with gadolinium (or CT brain with contrast, if MRI is not', 'feasible) will be performed in the screening period for patients with history of brain', 'metastases, or for whom there is clinical suspicion of brain metastases. Patients with', 'brain metastases that are \"not active\" (see Section 6.2.2) who are enrolled on the study', 'should have brain imaging at each response assessment, or sooner if there is clinical', 'suspicion of worsening brain metastases during treatment.', 'All radiological scans will be submitted to central depository and may be reviewed centrally.', '7.2.3.', 'Survival Data Collection', 'Every effort will be made to collect survival data on all patients, including patients who withdraw', 'from the study for any reason but have not withdrawn consent to collect survival information. If', 'the death of a patient is not reported, the date of the last patient contact in this study will be used', \"in the determination of the patient's last known date of being alive.\", '7.2.4.', 'Quality of Life Questionnaires', 'Patient-reported outcomes will be measured at a frequency indicated in Table 1 and Table 2 using', 'the validated patient self-administered EORTC QLQ-C30 questionnaire. Patients will be asked to', 'Regeneron Pharmaceuticals, Inc.', 'Page 61 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}